TESAMORELIN 20mg

Tesamorelin is a synthetic research peptide and stabilized analog of growth hormone–releasing hormone (GHRH) designed to selectively activate the GHRH receptor and stimulate endogenous growth hormone secretion in experimental models. Preclinical and clinical research has focused on its role in modulating somatotropic signaling, lipid metabolism, and visceral adipose regulation through cAMP-dependent pituitary pathways. Tesamorelin is utilized in research investigating hypothalamic–pituitary axis dynamics, metabolic signaling, neuroendocrine regulation, and growth hormone–mediated tissue effects. 

Here’s a breakdown:

What It Does

Tesamorelin binds to GHRH receptors in the pituitary gland, stimulating growth hormone secretion. This, in turn, increases insulin-like growth factor 1 (IGF-1) levels in the blood — the main mediator of GH’s anabolic (muscle-building and fat-burning) effects.

Medical Use

Tesamorelin is FDA-approved under the brand name Egrifta® for:

• Reducing excess abdominal fat in HIV-associated lipodystrophy (fat accumulation due to antiretroviral therapy).

Off-Label / Research Uses

In the performance and anti-aging world, it’s often explored for:

• Reducing visceral and subcutaneous fat

• Improving muscle tone and recovery

• Enhancing sleep and cognitive function

• Improving skin elasticity and tissue repair

• Supporting natural GH levels in older adults

Administration

• Usually injected subcutaneously (under the skin) once daily.

• Common research doses: 1–2 mg per day, often before bedtime on an empty stomach to align with natural GH release.

Potential Side Effects

• Temporary injection site redness or irritation

• Water retention, mild joint pain, or carpal tunnel–like symptoms

• Insulin resistance or mild blood sugar elevation

• Nausea or tingling in hands/fingers

Half-Life & Onset

• Half-life: ~2 hours

• GH elevation peaks about 1–2 hours post-injection

• IGF-1 increase is gradual over days to weeks